Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple...

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Oligodendrocyte death is a key factor in multiple sclerosis (MS) pathogenesis.
• Current MS therapies primarily focus on immunomodulation with limited success in halting disease progression.
• Protecting oligodendrocytes presents a promising therapeutic avenue for MS.

Purpose of the Study:

• To investigate the potential of enhancing the integrated stress response (ISR) to protect oligodendrocytes.
• To evaluate the efficacy of the FDA-approved drug guanabenz in preventing oligodendrocyte loss and ameliorating MS pathology.

Main Methods:

• Assessed oligodendrocyte survival in culture and cerebellar explants under inflammatory conditions (interferon-γ).
• Utilized in vivo models, including CNS-specific interferon-γ expression and experimental autoimmune encephalomyelitis (EAE) in mice.
• Monitored clinical symptoms, oligodendrocyte survival, and immune cell infiltration in EAE models.

Main Results:

• Guanabenz enhanced oligodendrocyte survival in vitro and prevented hypomyelination in cerebellar explants.
• In vivo, guanabenz protected against interferon-γ-induced oligodendrocyte loss.
• Guanabenz treatment alleviated clinical symptoms in EAE mice, correlating with increased oligodendrocyte survival and reduced CD4+ T cell accumulation.
• The drug also ameliorated relapse in a relapsing-remitting EAE model.

Conclusions:

• Enhancing the integrated stress response with guanabenz offers a neuroprotective strategy for multiple sclerosis.
• Guanabenz demonstrates potential for protecting oligodendrocytes in the inflammatory central nervous system environment characteristic of MS.
• These findings support the development of ISR-enhancing therapies for MS treatment.